Are you Dr. Espinoza-Delgado?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 16 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3001 S Hanover St
Nia-Astra Unit, 5th Floor
Baltimore, MD 21225Phone+1 410-350-7317Fax+1 410-350-3979
Summary
- Dr. Igor Espinoza-Delgado, MD is an oncologist in Baltimore, Maryland.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Central University of VenezuelaClass of 1980
Clinical Trials
- Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma Start of enrollment: 1999 Sep 01
- Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2004 Jul 01
Publications & Presentations
PubMed
- 9 citationsDifferentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J. Norsworthy, Eunpi Cho, Jyoti Arora, Jeanne Kowalski, Hua Ling Tsai
Leukemia Research. 2016-10-01 - 27 citationsA phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemiaJonathan How, Mark D. Minden, Leber Brian, Eric Chen, Joseph Brandwein
Leukemia & Lymphoma. 2015-02-16 - 35 citationsA Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumorsDustin A. Deming, Jacob Ninan, Howard H. Bailey, Jill M. Kolesar, Jens C. Eickhoff
Investigational New Drugs. 2014-01-01
Grant Support
- Antitumor And Immunomodulatory Activities Of Bryostatin-National Institute On Aging2005
- Phase II Trial Of Bryostatin-1 And Rituximab In B CellNational Institute On Aging2004–2005
- Aging, Cancer, And The Immune SystemNational Institute On Aging2003–2005
- Antitumor And Immunomodulation: Bryostatin-1/Il-2National Institute On Aging2004
- Phase 2 Trial Of Bryostatin-1/Rituximab In B Cell CancerNational Institute On Aging2003
- Antitumor/Immunomodulatory Activities--Bryostatin-1/Il2National Institute On Aging2003
- Bryostatin-1 And IL-2 In Monocytes As APCNational Center For Research Resources2000–2001
- Trial Of Bryostatin/Il-2 To Enhance Antigen PresentationNational Cancer Institute1999
